New malaria antibody enters first human safety tests
NCT ID NCT07646353
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new antibody drug (GSK4425689A) designed to prevent malaria. Researchers will give the drug to 40 healthy adults either through an IV or a shot under the skin to check for side effects and how the body processes it. The goal is to see if it is safe enough for larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA,FALCIPARUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental malaria vaccine aims to block parasite growth
- New malaria drug interaction study launches in healthy volunteers
- New malaria shots could replace daily pills
- Breastfeeding moms with malaria: do drugs reach baby?
- New malaria pill shows promise in early trial
- One shot to stop malaria? new injection tested in rwanda